eFFECTOR Therapeutics, Inc. Warrant
EFTRW
EFTRW was delisted on the 2nd of July, 2024.
17 hedge funds and large institutions have $2.94M invested in eFFECTOR Therapeutics, Inc. Warrant in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 7 closing their positions.
19% less funds holding
Funds holding: 21 → 17 (-4)
48% less capital invested
Capital invested by funds: $5.66M → $2.94M (-$2.71M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
+$126K |
| 2 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
+$31.4K |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
+$17.5K |
| 4 |
ICM
III Capital Management
Boca Raton,
Florida
|
+$11.8K |
| 5 |
PA
Parallel Advisors
San Francisco,
California
|
+$4.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$213K |
| 2 |
Blackstone Inc
New York
|
-$163K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$129K |
| 4 |
AGM
Alpine Global Management
New York
|
-$65K |
| 5 |
MIG
Mariner Investment Group
Harrison,
New York
|
-$37K |
EFTRW Hedge Fund Activity: Q4 2021 in Review
17 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Warrant (EFTRW) for Q4 2021, worth a combined $2.94M — down 48% from $5.66M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of EFTRW and 3 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was Pura Vida Investments, opening a new position worth an estimated $126K. The largest seller was Monashee Investment Management, exiting entirely with an estimated $213K sold.
- 17 institutional investors held eFFECTOR Therapeutics, Inc. Warrant (EFTRW) as of Q4 2021, down from 21 in Q3 2021.
- Funds reported $2.94M of eFFECTOR Therapeutics, Inc. Warrant stock for Q4 2021, down 48% quarter-over-quarter.
- 3 funds opened new eFFECTOR Therapeutics, Inc. Warrant positions in Q4 2021 and 7 closed out, a net change of -4 holders.
- The largest eFFECTOR Therapeutics, Inc. Warrant buyer in Q4 2021 was Pura Vida Investments, an estimated $126K added.
- The largest eFFECTOR Therapeutics, Inc. Warrant seller in Q4 2021 was Monashee Investment Management, an estimated $213K sold.
Based on aggregated 13F filings for Q4 2021.